Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novartis
Mayo Clinic
Indiana University
Novartis
Emerald Clinical Inc.
Fox Chase Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
Northwestern University
Cancer Trials Ireland
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
University of Virginia
Novartis
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of California, San Francisco
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNICANCER
UNICANCER
Kidney Cancer Research Bureau
Centre Leon Berard
National Cancer Institute (NCI)
University of California, Irvine
Grupo Espanol de Tumores Neuroendocrinos
Dana-Farber Cancer Institute
Charite University, Berlin, Germany
University of Utah
University of Zurich
GlaxoSmithKline
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute, Naples
Hannover Medical School
Stanford University
Scandinavian Sarcoma Group
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Vector Oncology
GlaxoSmithKline
Grupo Español de Investigación en Cáncer de Ovario
Samsung Medical Center
GlaxoSmithKline
Centre Leon Berard
National Cancer Institute (NCI)
GlaxoSmithKline
SCRI Development Innovations, LLC